Equities analysts expect Natus Medical Incorporated (NASDAQ:BABY) to report earnings per share of $0.38 for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Natus Medical’s earnings, with the lowest EPS estimate coming in at $0.37 and the highest estimate coming in at $0.38. Natus Medical posted earnings per share of $0.39 during the same quarter last year, which would indicate a negative year over year growth rate of 2.6%. The firm is scheduled to issue its next quarterly earnings results before the market opens on Wednesday, October 25th.

According to Zacks, analysts expect that Natus Medical will report full-year earnings of $1.70 per share for the current year. For the next fiscal year, analysts anticipate that the firm will post earnings of $1.98 per share, with EPS estimates ranging from $1.90 to $2.05. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Natus Medical.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The business had revenue of $122.20 million during the quarter, compared to analysts’ expectations of $121.99 million. During the same quarter in the previous year, the business earned $0.39 EPS. The company’s revenue for the quarter was up 27.3% on a year-over-year basis.

Several brokerages have issued reports on BABY. Zacks Investment Research upgraded Natus Medical from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. BidaskClub cut Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $48.00.

Shares of Natus Medical (NASDAQ:BABY) traded up 0.25% during mid-day trading on Monday, hitting $40.20. The stock had a trading volume of 424,842 shares. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of 69.67 and a beta of 0.95. The company has a 50-day moving average of $37.32 and a 200 day moving average of $36.10. Natus Medical has a one year low of $31.65 and a one year high of $43.85.

In other news, Director William M. Moore sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the completion of the sale, the director now directly owns 30,410 shares in the company, valued at approximately $1,036,981. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Robert A. Gunst sold 4,400 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $35.17, for a total value of $154,748.00. Following the completion of the sale, the director now owns 50,850 shares of the company’s stock, valued at $1,788,394.50. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Riverhead Capital Management LLC lifted its position in Natus Medical by 90.9% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after acquiring an additional 1,364 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in shares of Natus Medical during the 1st quarter worth approximately $110,000. Sei Investments Co. lifted its position in shares of Natus Medical by 29.7% during the 2nd quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock worth $119,000 after buying an additional 728 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Natus Medical by 94.0% during the 1st quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 1,543 shares in the last quarter. Finally, Flinton Capital Management LLC lifted its position in shares of Natus Medical by 82.0% during the 2nd quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock worth $141,000 after buying an additional 1,700 shares in the last quarter. Institutional investors own 92.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/23/analysts-expect-natus-medical-incorporated-baby-will-announce-earnings-of-0-38-per-share.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.